On November 11, Centrus rose 5.58% in Pre-Market Trading, trading at $116.0 per share, with turnover of $0.6583 million.
The clearest catalyst in recent market updates was the company’s announcement that Kevin Graney joined the board, while sentiment also remained supported by analyst upgrades issued earlier, including Roth Capital’s upgrade to Buy with a $115 price target and Canaccord Genuity’s upgrade to Buy.
Background context remains mixed. Centrus reported third-quarter adjusted EPS of negative $0.49 on revenue of $55.5 million, both below expectations, and Jefferies subsequently cut its target price to $117 from $169. Even so, recent movement alerts linked the share rebound to post-earnings sentiment repair and broader strength across uranium and nuclear fuel names, with peers such as Cameco, Denison Mines, Energy Fuels, Uranium, and Nexgen Energy Ltd. also rising.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments